Healthcare / Medical DevicesShenzhen
$17.62
+0.90 (+5.38%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-91.3M · quality 78.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.7B
P/E
N/A
•EV/EBITDA
172.2x
↑ROE
-6.1%
↓Gross Margin
25.7%
↓Debt/Equity
0.64
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.6%
FCF CAGR
—
FCF margin
-7.0%
FCF / Net income
1.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.10B · net income $-69.4M · FCF $-77.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.10B | $1.10B | $1.06B | $1.19B | $1.18B |
| Net Income | $-69.4M | $-69.4M | $-71.4M | $-65.2M | $22.1M |
| EBITDA | $27.3M | $27.3M | $25.4M | $26.8M | $84.9M |
| EPS | -0.26 | -0.26 | -0.27 | -0.25 | 0.08 |
| Gross Margin | 25.7% | 25.7% | 27.1% | 32.4% | 30.2% |
| Operating Margin | -1.5% | -1.5% | -2.9% | 6.9% | 2.4% |
| Net Margin | -6.3% | -6.3% | -6.7% | -5.5% | 1.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.64 | 0.64 | 0.53 | 0.45 | 0.30 |
| Current Ratio | 1.59 | 1.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-77.0M | $-77.0M | $-112.4M | $-91.3M | $-71.1M |
| Returns | |||||
| ROE | -6.1% | -6.1% | -5.9% | -5.0% | 1.6% |
| Valuation | |||||
| P/E | — | — | — | — | 119.20 |
| EV/EBITDA | 172.22 | 172.22 | 71.55 | 103.38 | 30.97 |
| P/B | 4.10 | 4.10 | 1.35 | 2.05 | 1.86 |
| Growth & Yield | |||||
| Revenue Growth | 3.3% | 3.3% | -11.2% | 0.9% | — |
| EPS Growth | 3.6% | 3.6% | -10.2% | -390.9% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+131.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.27 → -0.26
Residual
+131.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.